Clinical outcomes of patients with coronavirus disease 2019 and active tuberculosis co-infection in Beijing China: A retrospective single-center descriptive study.

Yang, X; Wang, C; Xue, Y; Zhang, Y; Zheng, M; Sun, Q; Long, S; Wang, D; Yan, J; Liao, X; Zhang, T; Cao, L; Chen, Y; Ju, W; Zhang, J; Gao, M; Zhao, Y; Luu, LDW; Pan, J; Wang, Y; Wang, G

Clinical outcomes of patients with coronavirus disease 2019 and active tuberculosis co-infection in Beijing China: A retrospective single-center descriptive study.

Yang, X Wang, C Xue, Y Zhang, Y Zheng, M Sun, Q Long, S Wang, D Yan, J Liao, X Zhang, T Cao, L Chen, Y Ju, W Zhang, J Gao, M Zhao, Y Luu, LDW Pan, J Wang, Y Wang, G

Permalink

Publisher:: ELSEVIER
Publication Type:: Journal Article
Citation:: Infect Med (Beijing), 2025, 4, (1), pp. 100169
Issue Date:: 2025-03

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (2.22 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Yang, X
dc.contributor.author	Wang, C
dc.contributor.author	Xue, Y
dc.contributor.author	Zhang, Y
dc.contributor.author	Zheng, M
dc.contributor.author	Sun, Q
dc.contributor.author	Long, S
dc.contributor.author	Wang, D
dc.contributor.author	Yan, J
dc.contributor.author	Liao, X
dc.contributor.author	Zhang, T
dc.contributor.author	Cao, L
dc.contributor.author	Chen, Y
dc.contributor.author	Ju, W
dc.contributor.author	Zhang, J
dc.contributor.author	Gao, M
dc.contributor.author	Zhao, Y
dc.contributor.author	Luu, LDW
dc.contributor.author	Pan, J
dc.contributor.author	Wang, Y
dc.contributor.author	Wang, G
dc.date.accessioned	2025-09-03T07:42:57Z
dc.date.available	2025-01-23
dc.date.available	2025-09-03T07:42:57Z
dc.date.issued	2025-03
dc.identifier.citation	Infect Med (Beijing), 2025, 4, (1), pp. 100169
dc.identifier.issn	2097-0684
dc.identifier.issn	2772-431X
dc.identifier.uri	http://hdl.handle.net/10453/189574
dc.description.abstract	BACKGROUND: Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) co-infection (COVID-19-TB) has the potential to exacerbate lung damage; however, information about the clinical features of COVID-19-TB is limited. This study aims to clarify the clinical characteristics and outcomes of patients with COVID-19-TB. METHODS: In this single-center retrospective study, the clinical features and outcomes of patients with COVID-19 with active TB who were admitted to Beijing Chest Hospital, Beijing, China, from 1 December 2022 to 18 January 2023 were collected. The severity of COVID-19 and TB was graded according to guidelines from the World Health Organization. The relationships of demographic and clinical variables with intensive care unit (ICU) admission were evaluated using univariable and multivariable logistic regression models. RESULTS: Overall, 102 patients with COVID-19-TB were enrolled. The mean age was 54.5 years (range 36.5-70 years). The most common clinical manifestations were cough (68.63%), sputum production (53.92%), fever (51.96%), and ground-glass opacities (35.29%). Complications included acute respiratory distress syndrome (11.76%), sepsis (9.8%), and respiratory failure (7.84%). Patients with COVID-19-TB had high concentrations of various proinflammatory cytokines, including interferon-γ, interleukin-1β, interferon-γ-inducible protein 10 kD, and monocyte chemoattractant protein-1. Sixteen of the 102 patients with COVID-19-TB (15.69%) were admitted to the ICU, and 10 (9.80%) died during hospitalization. The significant risk factors for ICU admission were respiratory failure, pulmonary fungal infection, and ventilation and oxygen therapy. CONCLUSIONS: The mortality rate of COVID-19-TB was 9.80%. Several demographic and clinical characteristics were associated with adverse outcomes, indicating the importance of early recognition and treatment.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	ELSEVIER
dc.relation.ispartof	Infect Med (Beijing)
dc.relation.isbasedon	10.1016/j.imj.2025.100169
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Clinical outcomes of patients with coronavirus disease 2019 and active tuberculosis co-infection in Beijing China: A retrospective single-center descriptive study.
dc.type	Journal Article
utslib.citation.volume	4
utslib.location.activity	Netherlands
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.date.updated	2025-09-03T07:42:54Z
pubs.issue	1
pubs.publication-status	Published online
pubs.volume	4
utslib.citation.issue	1

Abstract:

BACKGROUND: Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) co-infection (COVID-19-TB) has the potential to exacerbate lung damage; however, information about the clinical features of COVID-19-TB is limited. This study aims to clarify the clinical characteristics and outcomes of patients with COVID-19-TB. METHODS: In this single-center retrospective study, the clinical features and outcomes of patients with COVID-19 with active TB who were admitted to Beijing Chest Hospital, Beijing, China, from 1 December 2022 to 18 January 2023 were collected. The severity of COVID-19 and TB was graded according to guidelines from the World Health Organization. The relationships of demographic and clinical variables with intensive care unit (ICU) admission were evaluated using univariable and multivariable logistic regression models. RESULTS: Overall, 102 patients with COVID-19-TB were enrolled. The mean age was 54.5 years (range 36.5-70 years). The most common clinical manifestations were cough (68.63%), sputum production (53.92%), fever (51.96%), and ground-glass opacities (35.29%). Complications included acute respiratory distress syndrome (11.76%), sepsis (9.8%), and respiratory failure (7.84%). Patients with COVID-19-TB had high concentrations of various proinflammatory cytokines, including interferon-γ, interleukin-1β, interferon-γ-inducible protein 10 kD, and monocyte chemoattractant protein-1. Sixteen of the 102 patients with COVID-19-TB (15.69%) were admitted to the ICU, and 10 (9.80%) died during hospitalization. The significant risk factors for ICU admission were respiratory failure, pulmonary fungal infection, and ventilation and oxygen therapy. CONCLUSIONS: The mortality rate of COVID-19-TB was 9.80%. Several demographic and clinical characteristics were associated with adverse outcomes, indicating the importance of early recognition and treatment.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/189574